From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

Tumor Angiogenesis and Metastasis in Melanoma

Tumor angiogenesis is thought to play a major role in determining the biologic behavior of neoplasms, including melanomas. Using immunostaining technology, investigators compared vascularity, tumor cell proliferation, and apoptosis rates in tumor cells from melanoma micrometastases and macrometastases obtained from lymph nodes. Macrometastases were identified on clinical examination. Micrometastases were clinically undetectable and were defined as foci of metastatic disease detected at the time of histologic examination.

The microscopic lesions had significantly fewer surrounding vessels than the clinically apparent lesions did. In contrast, the relative rates of proliferation and apoptosis were similar in the two types of lesions. The investigators conclude that the difference in vascularity may correlate with the difference in biologic behavior of micrometastases and macrometastases and may account for the apparent "dormant" state associated with micrometastases.

Comment: The investigators suggest that a "dormant" state may explain why patients with melanoma may develop metastases up to 40 years after a primary diagnosis, and that a balance of proliferation and apoptosis, controlled in part by low vascular supply, may account for this finding. These observations and the authors' analyses provide interesting new insights into the enigmatic behavior of some melanomas. It remains to be seen whether the observations will hold up to careful prospective study and will ultimately provide clinicians with prognostic information.

— BR Smoller

Published in Journal Watch Dermatology October 1, 1998

Citation(s):

Barnhill RL et al. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol 1998 134 991-995.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1998. Massachusetts Medical Society. All rights reserved.